News & Updates

An implantable tibial neuromodulation (ITNM) therapy results in statistically significant improvements in urge urinary incontinence (UUI), urinary frequency, and urgency symptoms, as shown in the TITAN 2 study. These benefits have been sustained through 12 months, with no serious safety concerns.

In the final analysis of the phase III PROTEUS trial, perioperative apalutamide + androgen deprivation therapy (APA+ADT) improves the curative success of radical prostatectomy (RP) in men with high-risk localized or locally advanced prostate cancer (HR LPC/LAPC).